相关实验视频

Updated: Jun 24, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

肺腺癌与EGFR生殖系突变的突变特征和临床结果

Kelsey Pan¹, Jennifer Owens², Yasir Elamin²

¹Department of Cancer Medicine, MD Anderson Cancer Center, University of Texas, Houston, Texas.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

|June 12, 2024

概括

生殖系EGFR突变是非小细胞肺癌 (NSCLC) 的不常见驱动因素,通常在非吸烟女性中发现. 奥西默蒂尼布的无进展存活率与生殖线EGFR突变与体质突变的NSCLC相似.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
肺部病理学肺部病理学

背景情况:

导致肺癌的生殖基因突变很少见,EGFR T790M在1%的非小细胞肺癌 (NSCLC) 中被发现.
获得的体质EGFR突变是肺腺癌发展的典型特征.
奥西默提尼布是EGFR T790M阳性肺癌的标准治疗方法.

研究的目的:

研究具有生殖线EGFR突变的NSCLC患者的特征和治疗结果.
为了比较ozimertinib在患有生殖线和体质EGFR突变的患者中的疗效.

主要方法:

肺癌月球拍摄GEMINI数据库的回顾性分析.
通过高变异等位基因分数识别生殖系突变 (约. 50%) 在无细胞DNA中,通过遗传检测证实.

主要成果:

确定了22名患有生殖线EGFR突变的患者,主要是EGFR T790M (95.5%).
该队列主要由女性 (86.4%),非吸烟者 (81.8%),白人 (86.4%),有肺癌家族史 (59.1%) 和第四阶段疾病 (72.7%) 组成.
在72.7%的患者中观察到小多焦点地面玻璃肺结节的独特放射图案. 一线奥西默蒂尼布治疗的无进展生存 (PFS) 中位数为16.9个月,任何一线奥西默蒂尼布治疗的20.4个月.

结论:

由生殖线EGFR突变驱动的NSCLC在非吸烟的白人女性中更为普遍,这些女性患有多焦点肺结节.
与体质EGFR突变NSCLC相比,奥西默蒂尼布在发育线EGFR突变NSCLC中表现出类似的PFS.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.遗传学是一个遗传学.细菌线的细菌线是什么在NSCLCLC中,我们可以看到.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Mutations

Mutations

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...